1. New Standards of Care in ALK-Translocated Advanced NSCLC

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Information Needed in Advanced NSCLC

5. Genetic Testing Techniques

6. ALK Translocations

7. A Newly Diagnosed Patient Case

8. Summary of Recent Clinical Trials

9. Ongoing Front-Line Clinical Trials

10. Faculty Experience With Alectinib Toxicities

11. Faculty Experience With Ceritinib Toxicities

12. Faculty Experience With Brigatinib Toxicities

13. Faculty Experience With Lorlatinib Toxicities

14. A Patient Who Received First-Line Crizotinib

15. Summary of Trials in Crizotinib-Refractory ALK-Positive NSCLC

16. A Patient Who Received Front-Line Alectinib

17. A Role for Immunotherapy?

18. IMPower150

19. Faculty Treatment Recommendations

20. Abbreviations

21. Abbreviations (cont)